Gastroesophageal reflux symptoms are common and occur in all of us from time to time. In others, reflux may be associated with ulcerative esophagitis. The symptoms may be aggravated by large meals, coffee, smoking and position. Physiological and pathological reflux can be separated by the frequency and duration of the exposure of the lower esophagus to acid. Pathological reflux results in symptoms and also esophagitis and ulceration in some patients. Although gastroesophageal reflux disease (GERD) is considered to result from a disorder of motility in the esophagus, gastric acid andpeptic activity are deemedpivotal to the initiation and continuation ofthe esophageal damage and the development ofsymptoms. Acid exposure in the esophagus is normally less than 4 percent of the 24 hours with a pH below 4. An increase over 4 percent of the time with a pH less than 4 is considered pathological. Hence, antisecretory drugs have become the principle approach to the treatment of reflux symptoms and esophagitis since they reduce the acidity of gastric juice and the activity ofpepsin. Importantly, they also reduce the volume ofgastric juice available for reflux into the esophagus.
INTRODUCTION
Gastroesophageal reflux disease (GERD)b is considered to be primarily a motility disorder characterized by abnormally frequent transient relaxations of the lower esophageal sphincter and loss of lower esophageal sphincter tone in the basal state [1] . Both of these abnormalities facilitate reflux of acidic gastric contents into the lower esophagus. Furthermore, clearance of the acidic refluxate from the esophagus is impaired in about 50 percent of patients with GERD [2] . This results in prolonged exposure of the mucosa of the lower esophagus to the damaging effects of acidic gastric contents. Despite the evidence of dysmotility and the defects in epithelial resistance in patients with GERD, gastric acid is considered of central importance to the initiation and continuation of the esophageal damage and the development of symptoms in patients with GERD and has been recognized as an independent pathophysiological factor in esophagitis [3] . Moreover, the successful results of antisecretory therapy in patients with erosive esophagitis support this view [4, 5] .
It is well accepted that the suppression of 24-hr gastric acid secretion significantly correlates with the healing rates of duodenal ulcer, gastric ulcer, and erosive esophagitis [4] [5] [6] [7] . Three primary parameters determining the effect of antisecretory treatment have been derived from antisecretory data. These are the degree of suppression of acidity, the duration of suppression of acidity over 24 hours and the duration of antisecretory treatment [7] [8] [9] [10] . Proton pump inhibitors (PPIs) produce a greater and longer-lasting degree of suppression of acidity than standard or higher doses of H2-receptor antagonists (H2RAs) in 24-hr pH studies. This significantly correlates with the speed of healing and relief of reflux symptoms in patients with grade II to IV esophagitis as shown in a recent meta-analysis of randomized controlled clinical trials consisting of 95 treatment arms and 7,635 patients with almost two times more patients healed and symptomfree per week when treated with PPIs than with H2RAs [11] . In patients refractory to standard doses of H2RAs, poor or no inhibition of gastric acid secretion has been considered the reason for the treatment failure [12] . Therefore, suppression of intragastric acidity over 24 hours plays a crucial role in the healing of esophagitis [6] . The longer and the greater the suppression of gastric acid secretion, the more esophagitis is healed [6] .
GASTRIC ACID SECRETION IN PATIENTS WITH GERD
Whether gastric acid hypersecretion exists in patients with GERD is controversial [13] [14] [15] [16] .The results from the critical analysis by Hirschowitz show no difference in basal and maximal gastric acid secretion between patients with endoscopically defined esophagitis and controls without esophagitis [13] . However, this study suffered from several methodological problems including possibly different techniques used for gastric analysis over the 14-year retrospective period and a questionable definition of hypersecretion (greater than 15 meq/hr was used) [17, 18] . The study by Collen et al. shows that a subgroup of patients were gastric acid hypersecretors although this result might be confounded by the inclusion of patients previously on H2-receptor antagonists studied during the period they might have acid rebound [14] . In a more recent large prospective study involving 228 patients, there was a significant difference in the mean basal acid output between patients with GERD (6.5 ± 5.6 meq/hr) and 65 normal controls (3.0 ± 2.7 meqfhr, p < .0001) [16] . Although 48.7 percent of the patients had a previous history of H2RA therapy, only 14.5 percent were taking H2RA during the two months prior to the gastric analysis [16] . Hypersecretion also was reported in the study of Johansson, who excluded patients taking H2RA [15] . Thus [19] . In asymptomatic subjects, the median acid exposure time was 1.1 percent, while in symptomatic patients without endoscopic esophagitis, the acid exposure time was 1.9 percent for patients with occasional symptoms (grade 1), 3 percent for those with one to three times occurrence of symptoms daily (grade 2) and 3.8 percent for patients with constant symptoms (grade 3), respectively. In patients with endoscopic esophagitis, the corresponding median acid exposure time was 6 percent, 10 percent and 11.2 percent for patients with symptom grades 1, 2 and 3, respectively [19] . The longer the duration of acid exposure, the more severe were the symptoms and the esophagitis. pH 4 as a threshold between pathological and physiological reflux Animal studies have demonstrated that esophageal mucosal injury is highly pH-dependent [21, 23] . Perfusion of the esophagus over a one-hour period with hydrochloric acid at varying pH induced esophagitis only when solutions of pH below 1.6 were used. The addition of porcine pepsin to the perfusate increased the severity of esophagitis and produced mucosal inflammation with solutions of between pH 1.3 and 2.3 [23] .
Distal intraesophageal pH varies from 5 to 7. A threshold of pH 4 has been suggested by most investigators as the optimal pH to discriminate aggressive and nonaggressive reflux [6, 20, 24] [30] . A significant correlation has been shown between area under the curve for H+ and all grades of esophagitis [30] .
DIFFERENCES BETWEEN ANTISE-CRETORY TREATMENTS IN SUPPRESSING GASTRIC ACID SECRETION
H2RAs
As described above, the frequency of acid reflux and the exposure time of the esophagus to acid in patients with GERD are both increased and correlate with the severity of the disease. Since most reflux occurs post-prandially and in the early evening, treatments to reduce acid reflux should target both basal acid secretion as well as meal-stimulated acid secretion. Pharmacologically, H2RAs are unable to overcome the integrated stimulus to acid secretion produced by a meal [31] [32] [33] [34] .
Results from a 24-hr pH monitoring study have shown that neither ranitidine 150 mg twice daily, nor an increased dose of 300 mg twice daily altered the 22-hour intraesophageal pH profile when compared with pretreatment recordings [35] . Attempts to improve the effect of H2RAs on reducing evening reflux, by dosing immediately after the evening meal have also been unsuccessful in reducing mealstimulated acid secretion albeit better than dosing at bedtime [34, 36] . The percentage of time with intraesophageal pH above 4 over 24 hours is about 10 hours for this dose regimen [34, 36] . Increasing doses of ranitidine from 150 mg three times a day to 300 mg three times a day significantly reduced the exposure time of the esophagus to acid from 6.8 percent to 2.5 percent [37] . This correlates significantly with the reduction in the frequency and the severity of heartburn. Furthermore, there is a correlation between basal acid secretion in patients with GERD and the dose of ranitidine required for healing esophagitis [16, 38] . However, increasing doses of ranitidine above 600 mg/day only increased modestly the antisecretory effect achieved with ranitidine 300 mg twice daily [39] . This may be due to the rapid development of tolerance to H2RAs as seen in normal volunteers [40] and in patients with reflux esophagitis [41] . PPIs PPIs are strong acid suppressing agents that specifically inhibit the enzyme of H+K+-ATPase and block the final common pathway for acid secretion. This is a prolonged and highly effective inhibition of both basal and stimulated gastric acid secretion to all known stimuli including meals. In comparison with placebo, omeprazole 10, 20 and 40 mg/day given in the morning significantly decreases the frequency of reflux episodes/hr and the mean percentage of total reflux time over the 24-hr period from 16.3 percent for the placebo treatment to 6.3 percent with omeprazole 10 mg, 0.9 percent with omeprazole 20 mg and 0.6 percent with omeprazole 40 mg/day [42] .
There are numerous comparative studies showing that PPIs are superior to H2RAs in the suppression of gastric acid secretion in patients with peptic ulcer and in the reduction of acid reflux in patients with GERD. In a randomized comparative study in patients with active gastric ulcer, lansoprazole 30 mg daily has been shown to be significantly more effective than famotidine 20 mg twice daily in maintaining intragastric pH above 3 throughout the 24-hr period (99 percent vs. 68 percent) with more ulcers healed with lansoprazole than with famotidine [43] . In another randomized, double-blind study in patients with grade II to IV esophagitis, Ruth et al. have shown that omeprazole 20 mg daily was significantly better than ranitidine 150 mg twice daily in reducing the total reflux time over the 24-hr period (2.5 percent vs. 6.3 percent, p = .02) and the frequency of reflux episodes (20 vs. 49 , p = .003) [44] . This correlated with a higher healing rate of esophagitis seen in patients treated with omeprazole than with ranitidine [44] . Even when compared with higher doses of H2RAs (e.g., ranitidine 300 mg or famotidine 40 mg twice daily), omeprazole 20 mg daily offers better results in the reduction of total reflux time (pH < 4) and the number of reflux episodes [45, 46] , two important determinants for healing GERD.
The suppression of gastric acid secretion has an important impact on the activity of pepsin as shown in animal studies. Although the relationship between hypersecretion of gastric pepsin and the severity of GERD is controversial [47, 48] , to inactivate peptic activity by suppressing gastric acid secretion is a well-accepted approach for the treatment of acid-related diseases. In analysis of 24-hr pH studies, Hirschowitz has shown that the diurnal intragastric pH during treatment with cimetidine 1000 mg/day or ranitidine 300 mg/day still allows pepsin to maintain significant proteolytic activity, whereas the pH achieved with omeprazole 30 mg/day is high enough largely to abolish peptic activity [49] . This may partly explain the superiority of PPIs over H2RAs in the treatment of acid-related diseases because of the successful elimination of an additional aggressive factor the peptic activity. It is known that lansoprazole has a better bioavailability than omeprazole after oral administration as shown in double-blind, randomized cross-over studies [50, 51] . After the first dose, the bioavailability of lansoprazole is greater than 85 percent and remains constant after repeated dosing [51] . This has been confirmed in our recent study in healthy volunteers in whom once daily lansoprazole 30 mg was used on four days, and the maximum antisecretory effect was obtained six hours after the first dose and was consistent with repeated dosing [52] , whereas the bioavailability of omeprazole is only 35 percent after the first dose and rises to about 60 percent after repeated dosing [53] . The plasma half-life of lansoprazole also is longer and the tmax is significantly shorter and, hence, lansoprazole has a faster onset of action than omeprazole [51, 54] . The pharmacokinetic differences between these two PPIs may explain the different effect of these two drugs on inhibiting gastric acid secretion and, thus, improvement of symptoms and possibly healing of GERD. In a placebo-controlled study, both lansoprazole 30 mg/day and omeprazole 20 mg/day were significantly better than placebo in increasing 24-hr intragastric pH and decreasing basal and pentagastrin-stimulated acid secretion [50] . However, the effect of lansoprazole on intragastric pH was consistently better than omeprazole. Lansoprazole had a significantly longer effect than omeprazole on maintaining the intragastric pH above 3 over the 24-hr period [50] . In a comparative study, Dammann et 
CLINICAL TRIALS IN THE TREAT-MENT OF GERD
The aims of medical treatment of GERD are to relieve the symptoms, to heal established esophageal mucosal damage and to prevent the development of complications. In order to achieve these goals, treatment needs either to prevent the reflux of acidic gastric contents into the esophagus or to reduce the injurious action of acid to a level that will allow healing of the esophageal mucosa to occur. Currently, there are no effective agents that can restore fully the motor defects that lead to pathological acid exposure in patients with GERD. Therefore, suppression of acid secretion remains the mainstay of medical treatment for patients with GERD.
H2RAs
The effect of H2RAs on the healing of erosive esophagitis has proved disappointing [11, 56] . Complete healing of severe esophagitis is rare although patients generally benefit from symptomatic improvement. It is known that H2RAs have certain pharmacokinetic and pharmacodynamic characteristics that limit the effect, such as short duration of effect, incomplete suppression of acid secretion, particularly that stimulated by meals [31] [32] [33] , the development of tolerance [41] and acid rebound [57] .
In a meta-analysis, We have show that early studies with standard dose of ranitidine 150 mg twice daily healed 38.6 percent of the patients with grades II to IV at four weeks and 54.3 percent at eight weeks [11, [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] . Complete symptom relief is seen in 42.4 percent of the patients at four weeks and 50.6 percent at eight weeks [11, 59, 61, 63, 69, 72] . In a placebo-controlled study, Robinson et al. showed that famotidine 20 mg twice daily improved symptoms in 69.9 percent of the patients without erosive esophagitis at two weeks and 81.8 percent at six weeks, which was significantly better than famotidine 40 mg nocte. and placebo [73] . The modest effect on erosive esophagitis seen with standard doses of H2RAs may result from its relatively weak effect on the suppression of gastric acid secretion as discussed above.
In order to increase the effect of healing esophagitis and relief of symptoms, higher doses of H2RAs and or more frequent dosing have been used and show better results than those achieved with standard doses [74] [75] [76] [77] . It is known that higher doses or more frequent dosing with H2RAs is associated with an increased suppression of gastric acid secretion over 24 hours, including meal-stimulated integrated acid secretion [75, 78] . This correlates with higher healing rates in patients with esophagitis and faster relief of symptoms than with standard doses of H2RAs in head-to-head comparison studies [58, 72, 74, 77] . The results of Johnson et al. show that, in patients with grade II to III esophagitis, treatment with ranitidine 300 mg four times a day healed 63 percent of the patients after four weeks and 75 percent after eight weeks, whereas in patients receiving ranitidine 150 mg twice daily, the healing rates were 29 percent at four weeks and 54 percent at eight weeks, respectively. The differences were highly significant (both p < .01) [58] . Significantly more patients had complete symptomatic relief on treatment with the higher dose of ranitidine at four and eight weeks (67 [64] . At four weeks, by intention-to-treat analysis, healing was achieved in 84 percent and 72 percent of the patients receiving lansoprazole 30 mg and 60 mg, respectively, whereas only 39 percent of the patients were healed with ranitidine 150 mg twice daily. There was a significant difference between the two doses of lansoprazole and ranitidine in the healing rates (p < .01). After eight weeks, the corresponding figures were 92 percent, 91 percent and 53 percent, respectively, with significantly more patients healed with lansoprazole than with ranitidine (p < .01). These differences were not influenced by smoking, drinking, patient age or sex and were seen across all grades of esophagitis [64] . Heartburn was significantly reduced in more patients treated with lansoprazole than with ranitidine at the four-and eight-week assessments either by physicians or by patients. Furthermore, patients receiving lansoprazole took less antacids on fewer days than those treated with ranitidine (p < .01) [64] . In a more recent study, Sontag et al. reported, in a randomized, double-blind study that the superiority of lansoprazole over ranitidine is also seen in healing erosive esophagitis in patients with Barrett's esophagus [82] . A total of 105 patients were randomly allocated to lansoprazole 30 mg daily and ranitidine 150 mg twice daily for eight weeks. A large and significant difference in healing rates was found between patients treated with lansoprazole and ranitidine being 32 percent at 2 weeks, 37 percent at four weeks and 33 percent at eight weeks, respectively (all p < .001) [82] . Significantly fewer patients in the lansoprazole group had heartburn during treatment than those in the raniditine group [82] .
Similar results have also been reported in early studies comparing omeprazole with standard dose of H2RAs [86, 87] . In a double-blind, multi-center, comparative study, Sandmark compared the effect of omeprazole 20 mg daily with ranitidine 150 mg twice daily on endoscopic healing of esophagitis and relief of symptoms in 144 patients with grades II to IV GERD [61] . The healing rates were 67 percent and 31 percent at four weeks in the omeprazole and ranitidine groups by perprotocol analysis, and 85 percent and 50 percent at eight weeks, respectively. Both differences were highly significant (p < .0001) [61] . More interestingly, 51 percent patients in the omeprazole group experienced substantial symptom improvement at the end of the first week of treatment, compared with only 27 percent of those receiving ranitidine (p = .009). Adverse events were comparable between these two groups [61] . A recent article combining two individual comparative studies with a total of 550 patients showed that omeprazole 20 mg daily is significantly more effective than standard-dose H2RAs in healing grade I to IV esophagitis and relieving reflux symptoms [88] . Moreover, the advantage of omeprazole over H2RAs was not influenced by patient age. Therefore, in comparison with standard doses of H2RAs, omeprazole has proved consistently more effective in providing faster relief of reflux symptoms and rapid healing of esophagitis.
High doses or frequent dosing regimens of H2RAs have been studied in order to increase the effect of H2RAs on healing esophagitis. Ranitidine 150 mg four times a day and 300 mg four times a day or 300 mg twice daily were used in three randomized, comparative studies showing similar results in healing esophagitis between these dose regimens [79] [80] [81] . Ranitidine 150 mg four times a day is as effective as ranitidine 300 mg four times a day in healing esophagitis of grades II to IV. Although significantly more patients were healed with higher doses of H2RAs than with the standard doses, about 30 percent of patients did not respond to these dose regimens after eight weeks of treatment. Furthermore, these doses were not effective in patients with severe esophagitis with an average of 50 percent unhealed at eight weeks, and treatment is not costeffective when compared with lansoprazole 30 mg daily or omeprazole 20 mg daily [89, 90] .
In numerous clinical trials, PPIs have proved more effective in healing erosive esophagitis than H2RAs with either standard or higher doses in patients with esophagitis and especially in those with severe disease or refractory to H2RAs. In a double-blind, randomized, multi-center study comparing the effect of lansoprazole 30 mg daily and ranitidine 300 mg twice daily on healing of patients with moderate and severe esophagitis, four and eight weeks of treatment with lansoprazole healed 79.4 percent and 91.2 percent patients by intention-to-treat analysis, respectively, while the corresponding figures for patients receiving ranitidine were 41.5 percent and 66.2 percent, respectively. There was a significant difference in healing rates between the two groups at both 4 and 8 weeks (p < .001) [91] . Symptom improvement as evaluated on a visual analog scale (VAS) was significantly better in patients treated with lansoprazole as compared to those on ranitidine.
The VAS decreased from 65.1 mm at entry to 13.5 mm at 4 weeks and 11.3 mm at 8 weeks in the lansoprazole group. In the ranitidine group, the corresponding figures were 63.5, 22.8 and 18.5 mm, respectively. Adverse events were comparable in both groups [91] . Therefore, even with a higher dose of H2RAs, PPIs proved to be consistently and significantly better for healing all grades of esophagitis and for the relief of reflux symptoms.
In another randomized, double-blind, multicenter study Bate et al. compared the differences between omeprazole 20 mg daily and cimetidine 400 mg four times a day in healing esophagitis and relief of symptoms in patients with grade I to IV esophagitis [92] . After four weeks of treatment, 56 percent of the patients in the omeprazole group were healed, whereas complete healing occurred in only 26 percent of the patients treated with cimetidine. The corresponding figures at eight weeks were 71 percent and 35 percent in patients treated with omeprazole and cimetidine, respectively. The difference was significant at both four and eight weeks between the two groups (p < .001) [92] . Moreover, healing was consistent at four and eight weeks among all grades of esophagitis in patients treated with omeprazole, while in the cimetidine group there was a significantly inverse correlation between endoscopic grades at entry and the healing rates at four and eight weeks (r = -0.98 and -0.99, respectively), and no patients with grade IV esophagitis at entry were healed after four and eight weeks. Increasing treatment duration from four weeks to eight weeks only healed 9 percent more patients with cimetidine, while the therapeutic gain was 15 percent with omeprazole [92] . Furthermore, significantly more patients became asymptomatic in the omeprazole group than in the cimetidine group at both four and eight weeks (46 [94] .
Another large study consisting of 604 patients from the U.K. showed similar results [95] . [96] . Since omeprazole 40 mg daily was used to compare with lansoprazole 30 mg daily in this study, it is difficult to make a comparison on a dose-by-dose basis.
As discussed earlier in this paper, reflux symptoms are significantly associated with esophageal acid exposure time (pH < 4). Since lansoprazole 30 mg daily has a rapid onset and longer-lasting suppression of acid secretion than omeprazole 20 mg daily [50, 51, 54, 55] , it is understandable why lansoprazole is superior to omeprazole in relieving reflux symptoms in patients with GERD.
SUMMARY AND CONCLUSIONS
Although GERD is recognized as a motility disorder, gastric acid together with pepsin have been considered as key factors in initiating and perpetuating the mucosal damage to the esophageal mucosa and the development of symptoms in patients with esophagitis. There is a dynamic relationship between the degree and duration of esophageal acid exposure and healing of esophagitis. The longer the intragastric pH is above 4, the more patients will be healed at any arbitrary time-point. Treatments [97] .
